* Expects to file an investigational new drug application
(IND) with FDA for its first IRAK inhibitor in 2017
Source text for Eikon:
Further company coverage:
The post BRIEF-Rigel Pharmaceuticals expects to file an investigational new drug application (IND) with FDA for its first IRAK inhibitor in 2017 appeared first on NASDAQ.